| Stereochemistry | ACHIRAL |
| Molecular Formula | C47H62N12O11S2 |
| Molecular Weight | 1035.199 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=NN(C)C2=C1N=C(NC2=O)C3=CC(=CC=C3OCC)S(=O)(=O)N4CCN(CCOC(=O)OCCN5CCN(CC5)S(=O)(=O)C6=CC=C(OCC)C(=C6)C7=NC8=C(N(C)N=C8CCC)C(=O)N7)CC4
InChI
InChIKey=MVYUCRDXZXLFSB-UHFFFAOYSA-N
InChI=1S/C47H62N12O11S2/c1-7-11-35-39-41(54(5)52-35)45(60)50-43(48-39)33-29-31(13-15-37(33)67-9-3)71(63,64)58-21-17-56(18-22-58)25-27-69-47(62)70-28-26-57-19-23-59(24-20-57)72(65,66)32-14-16-38(68-10-4)34(30-32)44-49-40-36(12-8-2)53-55(6)42(40)46(61)51-44/h13-16,29-30H,7-12,17-28H2,1-6H3,(H,48,50,60)(H,49,51,61)
| Molecular Formula | C47H62N12O11S2 |
| Molecular Weight | 1035.199 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lodenafil carbonate, a novel phosphodiesterase 5 inhibitor developed in Brazil. Lodenafil carbonate is a prodrug that is metabolized with formation of the active compound, lodenafil. Lodenafil carbonate participated in phase III clinical trial for erectile dysfunction and showed a satisfactory efficacy-safety profile.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
